<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156522">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078492</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01-19</org_study_id>
    <nct_id>NCT02078492</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management</brief_title>
  <official_title>A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in
      treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) that is widely used
      in the Emergency Department (ED) for the treatment of moderate-to-severe pain. Ketorolac is
      available in both oral and parenteral forms and possess significant analgesic potency.
      However, ketorolac provides few advantages over other currently available analgesics and its
      use is limited by a virtue of having an &quot;analgesic ceiling&quot; with the dose being 10mg as well
      as having a range of severe side effects, of which gastrointestinal hemorrhage is most
      concerning.The concept of an analgesic ceiling is that doses beyond this value (10mg) do not
      provide additional analgesia and do contribute to side effects. In spite of this, the
      majority of research conducted on ketorolac in the ED and recommendations in Tintinalli's
      Emergency Medicine Textbook advocating for use of three-to-six fold higher dosages.

      Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in
      treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The difference between 3 groups in pain relief at 30 minutes.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The difference between 3 groups in pain relief at 30 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of side effects related to administration of Ketorolac</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The rate of side effects related to administration of Ketorolac that will include:
acute gastrointestinal hemorrhage (required re-admission, EGD, colonoscopy or PRBC transfusion; new onset CHF; worsening of pre-existing CHF, new onset of renal or hepatic failure, severe allergic reactions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group 1 - 10 mg of Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 10 mg of Ketorolac for pain relief.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 15mg of Ketorolac.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 30mg of Ketorolac as a part of standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg of Ketorolac</intervention_name>
    <description>Patients will receive 10 mg of Ketorolac for pain control.</description>
    <arm_group_label>Group 1 - 10 mg of Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg of Ketorolac</intervention_name>
    <description>Patients will receive 15mg of Ketorolac for pain control.</description>
    <arm_group_label>Group 2 - 15mg</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg of Ketorolac</intervention_name>
    <description>Patients will receive 30mg of Ketorolac for pain control.</description>
    <arm_group_label>Group 3 - 30mg</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Severe flank and abdominal pain, severe musculoskeletal pain (traumatic and non-traumatic
        in origin), headache, dental pain.

        Exclusion Criteria:

        Age &gt;65, Active Peptic Ulcer disease, Acute Gastrointestinal Hemorrhage, Known Hx of Renal
        or Hepatic insufficiency, Hx of allergies to NSAIDS.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonios Likourezos, MA, MPH</last_name>
    <phone>718-283-6896</phone>
    <email>ALikourezos@maimonidesmed.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonios Likourezos, MA, MPH</last_name>
      <phone>718-283-6896</phone>
      <email>ALikourezos@maimonidesmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Illya Pushkar, MPH</last_name>
      <phone>7182836076</phone>
      <email>ipushkar@maqimonidesmed.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Rockoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Fromm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonios Likourezos, MA, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emil Soleyman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kanika Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Illya Pushkar, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Cohen, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Catapano MS. The analgesic efficacy of ketorolac for acute pain. J Emerg Med. 1996 Jan-Feb;14(1):67-75. Review.</citation>
    <PMID>8655940</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
